Perfusion Culture for Etanercept Folding Accuracy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing etanercept using recombinant DNA technology in CHO cells result in significant amounts of incorrectly or misfolded protein, which reduces yields and increases costs, and may be detrimental to patients, as only correctly folded protein is therapeutically effective.
Innovation Solution
A perfusion method involving cells expressing etanercept cultured in a medium with SFM4CHO or BalanCD/Hycell medium, supplemented with dexamethasone, N-acetylmannosamine, and galactose, where the culture medium is continuously or periodically refreshed, allowing for production at temperatures above 33°C to achieve greater than 40% correctly folded etanercept.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If etanercept is produced using recombinant DNA technology in CHO cells, then the protein can be manufactured, but a large amount of incorrectly folded and aggregated protein is produced, reducing yields and increasing costs
Solution Approach 1:
The patent applies parameter changes by optimizing culture temperature (raising it above 33°C), pH levels, and nutrient composition in the culture medium. These parameter modifications create favorable conditions that promote correct protein folding while reducing misfolding and aggregation, thereby improving both manufacturing precision and productivity
Solution Approach 2:
The patent introduces specific intermediary substances in the culture medium, including glucose, amino acids, vitamins, and supplements like transferrin and iron. These intermediaries act as mediators that support cellular metabolism and protein synthesis, enabling higher yields of correctly folded etanercept while maintaining folding accuracy
2Reliability
If conventional culture methods are used, then production can proceed, but incorrectly folded protein reduces therapeutic efficacy and may be detrimental to patients
Solution Approach 1:
The patent modifies critical process parameters including temperature (maintaining above 33°C), pH (7.0-7.5), and nutrient composition to create an optimized environment that ensures high reliability of therapeutic efficacy through correct protein folding, while simultaneously improving productivity
Solution Approach 2:
The patent implements monitoring and control systems that provide feedback on protein folding status and product quality. This allows real-time adjustment of culture conditions to maintain high ratios of correctly folded protein, ensuring both therapeutic reliability and productivity
3Productivity
If production costs are reduced by improving yields, then economic viability increases, but maintaining correct folding requires optimized process conditions
Solution Approach 1:
The patent optimizes culture medium composition by adjusting parameters such as glucose concentration, amino acid profiles, vitamin levels, and supplement additions. These parameter changes enable high yields of correctly folded etanercept while managing the complexity of medium formulation through systematic optimization
Solution Approach 2:
The patent employs composite culture media that combine multiple nutrients, growth factors, and supplements in specific proportions. This composite approach simplifies the overall process by using pre-formulated media compositions that simultaneously support high productivity and correct protein folding without requiring complex individual component control
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Production of etanercept using perfusion methods achieves attractive yields of properly folded protein. Desired temperature, feed media, titers and percent correctly folded protein are disclosed.